BOLT — Bolt Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $12.08m
- -$5.52m
- $7.70m
Brief: Bolt Biotherapeutics Appoints Nicole Onetto To Board Of Directors
Brief: Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating A Safe And Well-Tolerated Profile
Brief: Bolt Biotherapeutics To Present Interim Clinical Data On BDC-1001 Phase 1/2 Clinical Trial
Brief: Bolt Biotherapeutics Inc - On November 17, 2021, Board Unanimously Voted To Increase Number Of Directors On Board From Eight To Nine
Brief: Bolt Biotherapeutics Presents New Preclinical Data On Three Pipeline Programs
Brief: Bolt Biotherapeutics Announces Clinical Collaboration With Bristol Myers Squibb To Study BDC-1001 In Combination With Opdivo For Treatment Of HER2-Expressing Solid Tumors
Brief: Bolt Biotherapeutics And Innovent Biologics Announce Collaboration
Brief: Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results
Bolt Biotherapeutics Inc reports results for the quarter ended in June - Earnings Summary
U.S. RESEARCH ROUNDUP-Agree Realty, Douglas Emmett, Realty Income
Brief: Bolt Biotherapeutics Reports First Quarter 2021 Financial Results And Provides Business Highlights
Brief: Bolt Biotherapeutics Posts Qtrly Loss Per Share $14.58
NASDAQ RESUMED AT 09:37 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Sofinnova Venture Partners X LP Reports 8% Stake In Bolt Biotherapeutics
Bolt Biotherapeutics: Jumps in market debut
Brief: Bolt Biotherapeutics Shares Open 30.5% Above IPO Price In Nasdaq Debut
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM